The patent, ‘Modified anticholinergic neurotoxins as modulators of the autoimmune reaction’ describes a composition of matter and method of its use to treat multiple sclerosis in humans.
The composition is a modified anticholinergic alpha-neurotoxin.
Nutra Pharma CEO Rik J Deitsch said such patents are key to the continuing development of their pipeline and provide the value for eventual commercialization of the technology or out-licensing of the drugs.
"We currently own or license twelve patents that protect a broad range of drug and medical device technologies," Deitsch added.